Associated Papers
Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non-Small-Cell Lung Cancer According to ALK Fusion and Mutation Status.
Bazhenova L et al.
Clinical Lung Cancer, 2025
Epidermal Growth Factor Receptor Aberrations Identified by Next-Generation Sequencing in Patients with Metastatic Cancers.
Shin M et al.
Cancer Research and Treatment, 2025
Concurrent EGFR L858R and K860I mutations: PCR-negative but NGS-positive alterations that respond to EGFR inhibitors in non-small cell lung cancer.
Shi H et al.
Journal of Thoracic Disease, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Germline EGFR mutations in lung cancer (Review).
Liu M et al.
Oncology Letters, 2023
Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Du Z et al.
Biomolecules, 2023
Molecular Divergence upon EGFR-TKI Resistance Could Be Dependent on the Exon Location of the Original EGFR-Sensitizing Mutation.
Serna-Blasco R et al.
Cancers, 2022
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
Analysis of single-nucleotide polymorphisms in genes associated with triple-negative breast cancer.
G V et al.
Frontiers in Genetics, 2022
Identification of PKHD1 mutations in Brain, Breast and Rectal tumors by Next Generation DNA Sequencing.
Mohammed Almehmadi D et al.
The Gulf Journal of Oncology, 2021
Identification of the Unique Clinical and Genetic Features of Chinese Lung Cancer Patients With EGFR Germline Mutations in a Large-Scale Retrospective Study.
Lin X et al.
Frontiers in Oncology, 2021
Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer.
Abdel-Wahab R et al.
Scientific Reports, 2020
Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Williams EA et al.
Acta Neuropathologica Communications, 2020
Next generation DNA sequencing of atypical choroid plexus papilloma of brain: Identification of novel mutations in a female patient by Ion Proton.
Taher MM et al.
Oncology Letters, 2019
The Landscape of Atypical and Eukaryotic Protein Kinases.
Kanev GK et al.
Trends in Pharmacological Sciences, 2019
A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancer.
Kohsaka S et al.
Science Translational Medicine, 2017
Discrimination of driver and passenger mutations in epidermal growth factor receptor in cancer.
Anoosha P et al.
Mutation Research, 2015
ProKinO: a unified resource for mining the cancer kinome.
McSkimming DI et al.
Human Mutation, 2015
ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics.
Alaoui-Jamali MA et al.
Frontiers in Genetics, 2015
Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer.
Keam B et al.
International Journal of Clinical Oncology, 2014
A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.
Ai X et al.
Amino Acids, 2014
Two rare exon 21 EGFR mutations in patients treated with gefitinib.
Mompradé E et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2013
The value of biomarkers in patients with sarcomatoid carcinoma of the lung: molecular analysis of 33 cases.
Jiang X et al.
Clinical Lung Cancer, 2012
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Wu JY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma-like carcinomas.
Chang YL et al.
Cancer Science, 2011
Limited copy number-high resolution melting (LCN-HRM) enables the detection and identification by sequencing of low level mutations in cancer biopsies.
Do H et al.
Molecular Cancer, 2009
EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future.
Yang CH
Lung Cancer (amsterdam, Netherlands), 2008
High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.
Do H et al.
Bmc Cancer, 2008
Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer.
Hsieh MH et al.
Lung Cancer (amsterdam, Netherlands), 2006
Genetic Profiling of Non-Small Cell Lung Cancer in Moroccan Patients by Targeted Next-Generation Sequencing.
El Zaitouni S et al.
Technology in Cancer Research & Treatment, 0